Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin NSC 729968) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Trial Profile

A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin NSC 729968) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary) ; Paclitaxel
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Aug 2020 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2017 Results (n=563) of pooled data from eight trial (NCI-GOG 0186H, NCI-8601, NCIC-CTG IND.213, REO011, REO015, REO016, REO018 and REO021) assessing the safety and tolerability of intravenous pelareorep in combination with chemotherapy, were presented at the 42nd European Society for Medical Oncology Congress.
    • 27 Jul 2017 Results (n=108;from December 2010 to September 2014) published in the Gynecologic Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top